Management of dyslipidemia in HIV-infected patients.
Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.
Division of Infectious Diseases & Immunology, Bellevue Hospital Center, New York University School of Medicine, NY, USA.
Carlos D
CD
Malvestutto
Judith A
JA
Aberg